Edge Wealth Management’s Grace Therapeutics GRCE Stock Holding History

Edge Wealth Management’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3	Closed	-$1K	–	494
2015 Q4	$1K	Hold	3	–	–	﹤0.01%	446
2015 Q3	$1K	Hold	3	–	–	﹤0.01%	448
2015 Q2	$0	Hold	3	–	–	﹤0.01%	457
2015 Q1	$1K	Hold	3	–	–	﹤0.01%	433
2014 Q4	$1K	Hold	3	–	–	﹤0.01%	403
2014 Q3	$1K	Hold	3	–	–	﹤0.01%	399
2014 Q2	$2K	Hold	3	–	–	﹤0.01%	359
2014 Q1	$2K	Hold	3	–	–	﹤0.01%	372
2013 Q4	$2K	Buy	+3	New	+$2.46K	﹤0.01%	331

Other funds holding GRCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

IIM

Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Edge Wealth Management's GRCE Position: Q1 2016 in Review

Edge Wealth Management sold out of Grace Therapeutics (GRCE) in Q1 2016, closing a stake of 3 shares — an estimated $1K sold.

Edge Wealth Management first reported a position in GRCE in Q4 2013 and held it in 9 quarters. The position peaked at $2K in Q2 2014. 12 funds tracked by Wall St. Rank hold GRCE as of Q1 2016.

Edge Wealth Management reported no remaining Grace Therapeutics position as of Q1 2016 after selling out during the quarter.
Edge Wealth Management sold 3 Grace Therapeutics shares in Q1 2016, an estimated $1K.
Edge Wealth Management first reported a position in Grace Therapeutics in Q4 2013 and held it in 9 quarters.
Edge Wealth Management's Grace Therapeutics position peaked at $2K in Q2 2014.
12 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2016.

Based on Edge Wealth Management's 13F filing for Q1 2016, filed 8 Apr 2016.